Therefore, agents that inactivate the PI3K-Akt-signaling pathway are worthy of investigation for their use in treating prostate cancers, particularly those with aggressive biologic behavior related to defects in p53 function and signaling. This evidence concerns the gene AKT1 and Familial prostate cancer.